Stryker Corp
NYSE:SYK
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
337.37
403.53
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
SYK
stock under the Base Case scenario is
327.48
USD.
Compared to the current market price of 353.67 USD,
Stryker Corp
is
Overvalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Stryker Corp.
| US |
|
Abbott Laboratories
NYSE:ABT
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Stryker faces intensifying competition in orthopedic implants, particularly as rivals like Zimmer Biomet and Johnson & Johnson expand their robotic-assisted surgery capabilities. Losing pricing power and market share in this key revenue driver could pressure margins.
Acquisitions, such as the purchase of Wright Medical, bring integration challenges and heighten the risk of execution missteps. If Stryker fails to realize anticipated cost synergies or manage operational complexities, its earnings and growth could be adversely affected.
A slowdown in elective procedures or more restrictive hospital budgets could undermine demand for Stryker’s surgical equipment and implants, disproportionately impacting the company’s high-margin businesses in orthopedic reconstruction and medical instruments.
Stryker’s significant investments in surgical robotics, exemplified by its Mako robotic-arm system, position the company for sustained leadership in the fast-growing orthopedic surgical space, supporting premium pricing and high customer switching costs.
Consistent capital deployment toward strategic acquisitions has enabled Stryker to broaden its product portfolio across neurotechnology, spine, and medical surgical equipment. This strategy adds incremental revenue streams and allows cross-selling opportunities in a range of clinical settings.
Strong relationships with hospitals and surgeons, coupled with Stryker’s robust R&D engine, bolster the company’s ability to innovate. This competitive moat should help Stryker defend and expand its share in high-demand fields like joint replacement and endoscopy.
Revenue & Expenses Breakdown
Stryker Corp
Balance Sheet Decomposition
Stryker Corp
| Current Assets | 13.7B |
| Cash & Short-Term Investments | 3.3B |
| Receivables | 3.6B |
| Other Current Assets | 6.7B |
| Non-Current Assets | 33.3B |
| PP&E | 3.7B |
| Intangibles | 25.1B |
| Other Non-Current Assets | 4.5B |
| Current Liabilities | 7.4B |
| Other Current Liabilities | 7.4B |
| Non-Current Liabilities | 17.9B |
| Long-Term Debt | 14.8B |
| Other Non-Current Liabilities | 3B |
Free Cash Flow Analysis
Stryker Corp
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Stryker Corp
|
Revenue
|
24.4B
USD
|
|
Cost of Revenue
|
-8.6B
USD
|
|
Gross Profit
|
15.7B
USD
|
|
Operating Expenses
|
-10.3B
USD
|
|
Operating Income
|
5.4B
USD
|
|
Other Expenses
|
-2.5B
USD
|
|
Net Income
|
2.9B
USD
|
SYK Profitability Score
Profitability Due Diligence
Stryker Corp's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Stryker Corp's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
SYK Solvency Score
Solvency Due Diligence
Stryker Corp's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
Stryker Corp's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SYK Price Targets Summary
Stryker Corp
According to Wall Street analysts, the average 1-year price target for
SYK
is 437.04 USD
with a low forecast of 320.88 USD and a high forecast of 488.25 USD.
Dividends
Current shareholder yield for
SYK is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
SYK
stock under the Base Case scenario is
327.48
USD.
Compared to the current market price of 353.67 USD,
Stryker Corp
is
Overvalued by 7%.